🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Pancreatic Cancer
Clinical trial register · China

Pancreatic Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 53 Beijing 25 Wuhan 15 Hangzhou 13 Nanjing 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University14 Changhai Hospital9 Tianjin Medical University Cancer Institute and Hospital7 Ruijin Hospital7 Peking Union Medical College Hospital7
Site location
Shanghai53 Beijing25 Wuhan15 Hangzhou13 Nanjing12
All 38 locations
Target enrolment
to

Pancreatic Cancer trials in China

132 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
NCT06326736Pancreatic Cancer
DrugsAbraxane·Camrelizumab·Gemcitabine
Jinling Hospital, China
Phase EARLY_PHASE1
12
Nanjing
2024-04
Recruiting
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
NCT06353646Pancreatic Cancer
DrugsXH001·Ipilimumab·Sintilimab
Wu Wenming
Not applicable
28
Beijing
2024-03-12
Recruiting
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
NCT06196788Pancreatic Cancer
DrugsNab-paclitaxel·Gemcitabine
Fudan University
Phase 2
30
Shanghai
2024-03-01
Not yet open
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer
NCT06217042Pancreatic Cancer
DrugsHR070803·5Fluorouracil·Calcium folinate·Capecitabine
Fudan University
Phase 3
524
Shanghai
2024-02-05
Not yet open
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
NCT06234072Pancreatic Cancer
DrugsGemcitabine alone·Gemcitabine
Shenzhen University General Hospital
Phase 2
120
Shenzhen
2024-02
Recruiting
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
NCT06151262Pancreatic Cancer
DrugsTrilaciclib·MFOLFIRINOX
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
30
Nanjing
2024-01-20
Recruiting
Bile Omics for Diagnosing Indeterminate Biliary Strictures
NCT07007832Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Strictures of Unknown Origin
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Observational
260
Shanghai
2024-01-01
Not yet open
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
NCT06156267Pancreatic Cancer
DrugAdebrelimab
Fudan University
Phase EARLY_PHASE1
30
Shanghai
2024-01
Recruiting
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
NCT06166147Pancreatic Cancer
Fudan University
Observational
276
Shanghai
2023-12-18
Recruiting
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
NCT06139042Liver Cancer, Biliary Tract Cancer, Pancreatic Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,608
Hangzhou
2023-11-01
Recruiting
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
NCT06008288KRAS P.G12C, Pancreatic Cancer, Solid Tumor
DrugGlecirasib
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Recruiting
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
NCT06389760Pancreatic Cancer
DrugsMFOLFIRINOX·Nimotuzumab
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
57
Nanjing
2023-10-18
Recruiting
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
NCT06307080Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
12
Shanghai
2023-10-08
Not yet open
Canagliflozin With Gemcitabine in Pancreatic Carcinoma
NCT05903703Pancreatic Cancer
DrugGemcitabine
Zhang Xiaofeng,MD
Not applicable
20
Hangzhou
2023-10-01
Recruiting
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
NCT05911217Pancreatic Cancer
DrugCT041 autologous CAR T-cell
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Recruiting
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
NCT05740956Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostatic Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
318
Beijing
2023-06-09
Recruiting
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
NCT05859750Pancreatic Cancer
Drugs5-Fluorouracil/Leucovorin·Cadonilimab·Irinotecan·Nab-paclitaxel
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Recruiting
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
NCT05802407Pancreatic Cancer, Resectable Carcinoma
Peking Union Medical College Hospital
Not applicable
100
Beijing
2023-02-01
Recruiting
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT05802394Pancreatic Cancer, Locally Advanced
Peking Union Medical College Hospital
Not applicable
100
Beijing
2023-02-01
Recruiting
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
NCT05827796Pancreatic Cancer
DrugsKN046·IN10018·Albumin-Bound Paclitaxel·Gemcitabine
InxMed (Shanghai) Co., Ltd.
Phase 1/2
70
Shanghai
2022-12-08
Recruiting
A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
NCT06245330Solid Tumor, Pancreatic Cancer
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
180
Changchun
2022-07-07
Recruiting
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
NCT04146298Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma, Advanced Cancer
DrugsFludarabine·Cyclophosphamide
Changhai Hospital
Phase 1/2
30
Shanghai
2021-10-21
Recruiting
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
NCT05218889Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
DrugsSurufatinib·Camrelizumab·Nab-paclitaxel·Tislelizumab
Chinese PLA General Hospital
Phase 1/2
90
Beijing
2021-08-04
Recruiting
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
NCT05035147Pancreatic Cancer
DrugAlbumin-Bound Paclitaxel
Tianjin Medical University Cancer Institute and Hospital
Phase 4
934
Tianjin
2021-03-25
Recruiting
Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)
NCT04743479Pancreatic Cancer, Diabetes, Familial Pancreatic Cancer, Pancreatic Cystic Neoplasm
Changhai Hospital
Observational
5,000
Shanghai
2020-12-01
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
DrugsSaruparib·Camizestrant·Datopotamab Deruxtecan·Trastuzumab deruxtecan
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Recruiting
Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE
NCT06849063Pancreatic Cancer
Yu Shi
Observational
200
Shenyang
2020-10-09
Active, closed
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
NCT04025840Pancreatic Cancer, Surgery, Epidural Block, Dexamethasone
DrugDexamethasone
Peking University First Hospital
Phase 4
260
Beijing
2019-09-11
Recruiting
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
NCT04084496Pancreatic Cancer
DrugFolfirinox
Sun Yat-sen University
Phase 2
80
Guangzhou
2019-09-01
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Beijing, Changchun, Chongqing, Guangdong, Guangzhou, Harbin, Hubei, Jiangsu
2019-03-15
Recruiting
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
NCT03498326Pancreatic Cancer, Chemotherapy Effect
DrugGemcitabine
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
480
Hangzhou
2018-04-02
Rows per page Showing 101–132 of 132
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/pancreatic-cancer?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 132 of those studies listing the condition Pancreatic Cancer.

How many Pancreatic Cancer trials are recruiting in China?

91 of the 132 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 31 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.